A Double-Blind, Paralleled Study Comparing Efficacy/Safety of Solifenacin to Tolterodine in Overactive Bladder Patients

• Status: Completed
• Trial end date: 2008-03-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the efficacy and safety of solifenacin succinate (Vesicare) 5mg OD in subjects with overactive bladder compared to tolterodine wmg, bid

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Astellas Pharma Inc
• Treatments: Solifenacin Succinate; Tolterodine Tartrate

Criteria

Inclusion Criteria:

• Patients willing and able to complete the micturition diary correctly

• Patients experiencing frequency of micturition as verified in the diary

• Patients experiencing significant post void residual volume

• OAB symptoms including urinary frequency, urgency or urge incontinence for 3 months or more.

Exclusion Criteria:

• Significant post void residual volume

• Patients with indwelling catheters or practicing intermittent self- catheterization

• Known or suspected hypersensitivity to solifenacin succinate or other anticholinergics or lactose